Intelligent Bio Solutions Q1 2027 earnings

INBS · 2026-11-10 16:30 AMC ET · 8-K on SEC

Record quarterly revenue of $1.39 million, up 25% year-over-year and 21% sequentially, with gross profit margin expanding to 54.5%.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.39M+25%+21%Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Cartridge sales$849,000+32%61%Higher-margin cartridge sales
Reader sales$542,000N/A39%Reader sales not explicitly quantified in revenue growth, implied by installed base growth

Margins and costs

  • Gross margin 54.5% (prior 46.6%, change +7.9 pp)
  • Operating expenses $3.65M (+7.8% YoY)
  • One-offs in the quarter Impairment of long-lived assets $261,780 (prior year only); Realized foreign exchange loss $5,344
  • Effective tax rate N/A (GAAP loss)
  • Non-GAAP bridge No non-GAAP reconciliation provided in the filing.

KPIs

MetricActualPrior quarterPrior yearChange
Installed baseN/AN/A22% YoY growthN/A
Cartridge sales growth32% YoY35% QoQN/AN/A
Cash and cash equivalents$5.93M$3.99MN/A+48.5%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue grew 25% year-over-year and 21% sequentially to a record $1.39 million, driven by a 32% increase in higher-margin cartridge sales, which represented 61% of total revenue.
  • EPS story Net loss per share improved to -$0.86 from -$3.49 year-over-year, driven by revenue growth and margin expansion.
  • One-off check Impairment of long-lived assets of $261,780 occurred in the prior year only.

The good

  • Record quarterly revenue of $1.39 million
  • Gross profit margin expanded to 54.5%
  • Cartridge sales grew 32% year-over-year and 35% sequentially

The bad

  • Net loss of $2.67 million
  • SG&A expenses increased 4.7% year-over-year to $2.58 million

The ugly

  • none

Open questions

  • The filing does not disclose the specific revenue contribution of reader sales versus other products.
  • The filing does not disclose the current installed base count or growth rate.
Full release

Intelligent Bio Solutions (INBS) earnings release, November 10, 2026

Intelligent Bio Solutions Inc. (INBS) · Form 8-K, Item 2.02 · Filed · SEC filing

Press

Release

Intelligent

Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year

Growth

Revenue up 25% year-over-year and 21% sequentially, marking third consecutive quarter above $1 million

Higher-margin cartridge sales grew 32% year-over-year and 35% sequentially, representing 61% of total revenue

Gross profit margin expanded to 54.5%, up from 46.6% in the prior-year quarter

Company submitted its FDA 510(k) premarket notification during the quarter, a key step toward planned U.S. market entry

NEW

YORK, November 10, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2026.

“Fiscal first quarter revenue was the highest quarterly revenue in our Company’s history,” said Harry Simeonidis, President and

CEO at Intelligent Bio Solutions.

“Each reader draws on a recurring supply of higher-margin cartridges, which is driving most of our revenue growth. Our business continues to scale with improving unit economics, including expanding gross profit margins driven by manufacturing efficiencies and a higher share of revenue from higher-margin cartridge consumables.”

Mr.

Simeonidis continued, “In September, we submitted our 510(k) premarket notification to the FDA for the Intelligent Fingerprinting

Drug Screening System, the culmination of the clinical program we executed throughout 2026 and a key step toward our planned entry into the multi-billion-dollar U.S. drug screening market. Going forward, we will continue to invest in the clinical and regulatory work behind our 510(k) submission while maintaining discipline across the rest of the business.”

Product

Revenue Breakdown

Three

Months Ended September 30, 2026 (Q1 Fiscal 2027):

Fiscal

First Quarter 2027 and Subsequent Highlights

The fiscal first quarter extended INBS’s consistent run of growth, with the installed base built through prior reader placements continuing to drive recurring, higher-margin cartridge demand. With its 510(k) submission complete, record quarterly revenue, and expanding gross profit margins, management believes the Company is well-positioned to continue its growth through fiscal 2027 as it pursues its planned entry into the multi-billion-dollar U.S. drug screening market.

About

Intelligent Bio Solutions Inc.

Intelligent

Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The

Company believes that its Intelligent Fingerprinting Drug Testing Solution, comprising its portable, on-site Intelligent Fingerprinting

Drug Screening System (“System”) and its Confirmatory Analysis Kit for back-to-lab testing, will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a fast, hygienic, and cost-effective solution, the System screens for the recent use of common drugs of abuse, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool across workplace, law enforcement, and government settings. The Company’s current customer segments outside the U.S. include construction and engineering, manufacturing, transport and logistics, mining, energy and utilities, government and public services, law enforcement and forensics, and drug treatment and rehabilitation.

Intelligent

Bio Solutions Inc. is an authorized distributor of the SMARTOX SmarTest Patch. The SmarTest Patch is a discreet, water-resistant, and tamper-evident device worn on the skin for 7 to 10 days at a time, continuously collecting sweat to detect a broad range of substances, including cocaine, opiates, methamphetamine, marijuana, and fentanyl. The differing detection windows of the SmarTest Patch and the System allow the Company to address both short- and long-term detection needs while maintaining a consistent, non-invasive, sweat-based approach.

For more information, visit: https://ibs.inc/

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025
Revenue1,391,8351,111,797
Cost of revenue (exclusive of amortization shown separately below)-633,831-593,506
Gross profit758,004518,291
Other income
Government support income205,501193,267
Operating expenses
Selling, general and administrative expenses-2,579,641-2,706,889
Development and regulatory approval expenses-829,544-486,169
Depreciation and amortization-237,067-257,907
Impairment of long-lived assets-261,780
Total operating expenses-3,646,252-3,712,745
Loss from operations-2,682,747-3,001,187
Other income (expense), net
Interest expense-1,435-2,309
Realized foreign exchange loss-5,344
Interest income21,0918,504
Total other income, net14,3126,195
Net loss-2,668,435-2,994,992
Net loss attributable to non-controlling interest-10,133-11,986
Net loss attributable to Intelligent Bio Solutions Inc.-2,658,302-2,983,006
Other comprehensive (loss) income
Foreign currency translation (loss) gain-52,26748,716
Total other comprehensive (loss) income-52,26748,716
Comprehensive loss-2,720,702-2,946,276
Comprehensive loss attributable to non-controlling interest-10,133-11,986
Comprehensive loss attributable to Intelligent Bio Solutions Inc.-2,710,569-2,934,290
Net loss per share, basic and diluted-0.86-3.49
Weighted average shares outstanding, basic and diluted3,095,306854,693

Balance Sheet

As of September 30, — Condensed Consolidated Balance Sheets

As of September 30, – 2026 – (Unaudited)As of June 30, – 2026
Current assets
Cash and cash equivalents5,929,8713,992,312
Accounts receivable, net999,756848,464
Inventories, net478,048418,577
Research and development tax incentive receivable529,433806,951
Other current assets1,108,3551,030,932
Total current assets9,045,4637,097,236
Property and equipment, net278,000294,399
Operating lease right-of-use assets1,702,3371,751,040
Intangibles, net2,595,8752,799,161
Total assets13,621,67511,941,836
Current liabilities
Accounts payable and accrued expenses3,669,0884,130,213
Current portion of operating lease liabilities152,700147,005
Current employee benefit liabilities756,680651,706
Total current liabilities4,578,4684,928,924
Employee benefit liabilities, less current portion54,94749,931
Operating lease liabilities, less current portion1,635,7321,672,155
Total liabilities6,269,1476,651,010
Shareholders’ equity
Common stock, $0.01 par value, 100,000,000 shares authorized, 3,316,815 and 3,316,803 shares issued and outstanding, as of September 30, 2026, respectively; 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively33,16829,056
Treasury stock, at cost, 12 shares as of September 30, 2026 and June 30, 2026, respectively-1-1
Additional paid-in capital85,770,29880,992,006
Accumulated deficit-77,622,342-74,964,040
Accumulated other comprehensive loss-598,453-546,186
Total consolidated Intelligent Bio Solutions Inc. equity7,582,6705,510,835
Non-controlling interest-230,142-220,009
Total shareholders’ equity7,352,5285,290,826
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY13,621,67511,941,836

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, secure regulatory clearance or approvals, including the timing and outcome of the FDA’s review of its 510(k) premarket notification, and timelines to enter the U.S. market, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including

“believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,”

“intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those... (truncated)S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company

Contact

Intelligent

Bio Solutions Inc. info@ibs.inc

Investor

& Media Contact

Valter

Pinto, Managing Director

KCSA

Strategic Communications

PH:

(212) 896-1254

INBS@kcsa.com

Financial

Tables to Follow

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Balance Sheets

Intelligent

Bio Solutions Inc.

Condensed

Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.